Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.

Cancer Chemother Pharmacol · 2026 · PMC13167888 · PMID 42118353

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

When exposed to 0.1 μM of the TKI, the intracellular imatinib concentration in P-gp overexpressing cells was significantly reduced ( p = 0.0138), whereas intracellular reductions of asciminib, dasatinib and bosutinib of 16.7%, 9.6% and 9.7%, respectively, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.